TITLE

Long-awaited opioid REMS affects prescribers more than dispensers

AUTHOR(S)
Thompson, Cheryl A.
PUB. DATE
June 2011
SOURCE
American Journal of Health-System Pharmacy;6/1/2011, Vol. 68 Issue 11, p963
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
61141651

 

Related Articles

  • Extended-release and long-acting opioid medications.  // WHO Drug Information;2012, Vol. 26 Issue 3, p265 

    The article reports on a 2012 decision which the U.S. Food and Drug Administration made to approve a risk evaluation and mitigation strategy for extended-release and long-acting opioids.

  • Risk Evaluation and Mitigation Strategies for Older Adults with Persistent Pain. Arnstein, Paul; Herr, Keela // Journal of Gerontological Nursing;Apr2013, Vol. 39 Issue 4, p56 

    The U.S. Food and Drug Administration issued Risk Evaluation and Mitigation Strategies for certain analgesic agents, but all medicines for older adults warrant risk-reduction considerations. Although not all older adults have pain, a higher prevalence of persistent pain exists in this...

  • US Food and Drug Administration's Risk Evaluation and Mitigation Strategy for Extended-Release and Long-Acting Opioids. Mercadante, Sebastiano; Craig, David; Giarratano, Antonello // Drugs;2012, Vol. 72 Issue 18, p2327 

    Prescriptions for opioid analgesics to manage moderate-to-severe chronic non-cancer pain have increased markedly over the last decade. An unintentional consequence of greater prescription opioid utilization has been the parallel increase in misuse, abuse and overdose, which are serious risks...

  • Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose? Bannwarth, Bernard // Drugs;2012, Vol. 72 Issue 13, p1713 

    During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already...

  • Proposal to improve MedWatch: Decentralized, regional surveillance of adverse drug reactions. Motl, Susannah; Timpe, Erin; Eichner, Samantha // American Journal of Health-System Pharmacy;9/1/2004, Vol. 61 Issue 17, p1840 

    Recommends improvements to MedWatch, the safety information and adverse-event reporting program of the United States Food and Drug Administration. Regional surveillance of adverse drug reactions (ADR); Need for pharmacists to be vigilant in detecting and reporting suspected ADR; Continuing...

  • FDA Remodels REMS for Opioid Medications. Stone, Alec // ONS Connect;Sep2012, Vol. 27 Issue 9, p18 

    The article offers information on the remodeling of the risk evaluation and mitigation strategy (REMS) by the U.S. Food and Drug Administration (FDA).

  • FDA advises caution for use of methadone. Crespi-Lofton, Judy // Pharmacy Today;Feb2007, Vol. 13 Issue 2, p38 

    The article focuses on the warning given by the U.S. Food and Drug Administration (FDA) regarding the use of methadone. The public health advisory issued by the FDA on November 27, 2006 followed reports on the life threatening effects of the drug including respiratory and heart complications....

  • Combination phentermine and topiramate effective obesity therapy.  // Australian Journal of Pharmacy;Oct2011, Vol. 92 Issue 1097, p81 

    The article presents information on an effective treatment of obesity by the controlled-release combination of drugs phentermine and topiramate. As stated, this combination of drugs is expected to be known by a proposed name Qnexa which is not approved by the U.S. Food and Drug Administration...

  • The class of 1997 -- part 2. Vinson, Michael C.; Davis, W. Marvin; Waters, I. Wade // Drug Topics;3/2/98, Vol. 142 Issue 5, p86 

    Part II. Focuses on continuing education while highlighting thirty-nine new molecular chemical entities which were approved by the United States Food and Drug Administration in 1997, referencing to the remaining 18 NMEs and the three newly approved diagnostic entities. Listing of the entities;...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics